PRESS RELEASE
News
-
-
PRESS RELEASE
Oxurion signs a letter of intent for the planned acquisition of a preclinical microbiology CRO to diversify and strengthen its presence in the Toulouse region
Oxurion NV announces LOI to acquire 70% share capital of preclinical microbiology services company. Economic details of the transaction and growth projections disclosed -
PRESS RELEASE
Oxurion signe une lettre d'intention pour l'acquisition projetée d'une CRO de services précliniques en microbiologie afin de se diversifier et de renforcer sa présence en région toulousaine
Oxurion NV signe une lettre d'intention pour l'acquisition de 70% d'une société spécialisée en microbiologie appliquée à la santé humaine et animale, dermocosmétiques et nutraceutiques -
-
-
-
-
-
-
PRESS RELEASE
Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV received transparency notifications from Atlas Special Opportunities II, LLC regarding its share ownership crossing thresholds under Belgian Transparency legislation. Oxurion is a biopharmaceutical company focusing on therapeutic innovation and clinical research technologies
